Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...

Oncodermatology is evolving with nonsurgical approaches and immune checkpoint inhibitors, improving outcomes in aggressive ...

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

The Maui Derm 2026 meeting featured in-depth discussion surrounding all areas of dermatology. Here, The American Journal of Managed Care ® asked speakers and attendees what their ...

The Coalition’s Conversation podcast series is a 3-part discussion on how employers can incorporate glucagon-like peptide-1 (GLP-1) therapies into a sustainable strategy to address obesity and weight ...

Na’ama Avitzur, MD, is a pulmonologist and a fellow at the University of British Columbia, researching interstitial lung disease and an internal medicine physician. A European Respiratory Journal ...

Telomere length and polygenic risk scores (PRS) are linked to idiopathic pulmonary fibrosis (IPF) risk, especially in noncarriers of rare genetic variants. The study identified rare damaging variants ...

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.

While the cost of health care remains the dominant worry among Americans, the process of obtaining prior authorization from ...

Panelists discuss how advanced practice providers (APPs) play a central role in identifying and managing amyloid-related ...

Aquestive Therapeutics announced it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for Anaphylm (dibutepinephrine) Sublingual Film, a noninvasive ...

Hair regrowth efficacy is the primary concern for AA patients, with insurance coverage and flare-up prevention also important ...